{
    "clinical_study": {
        "@rank": "30042", 
        "arm_group": [
            {
                "arm_group_label": "NeuroAD", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training"
            }, 
            {
                "arm_group_label": "Sham NeuroAD", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure."
            }
        ], 
        "brief_summary": {
            "textblock": "Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer\n      for the treatment of Alzheimer patients."
        }, 
        "brief_title": "Effect of NeuroAD on Alzheimer Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "Synchronized TMS and cognitive training for the treatment of mild to moderate Alzheimer's\n      patients. Treatment is delivered 5 days a week, for 6 weeks, visit is about an hour long.\n\n      Evaluation is by neuropsychological evaluation at 6 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female age 60-90 years\n\n          2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to\n             the DSM-IV criteria.\n\n          3. MMSE score 18 to 26\n\n          4. Adas-cog above 17\n\n          5. Physically acceptable for the study as confirmed by medical history and exam.\n\n          6. Spouse, family member or professional caregiver agree and capable of taking care and\n             be responsible for the participation of the patient in the study (answering questions\n             regarding the patient's condition and assuming responsibility for medication)\n\n          7. Agreement to participate in approximately 14 weeks during the study.\n\n          8. Normal or corrected to normal ability to see and to hear.\n\n          9. Korean as primary language\n\n         10. 8th grade education minimum\n\n        Exclusion Criteria:\n\n          1. CDR 0  or 3\n\n          2. Severe agitation;\n\n          3. Mental retardation;\n\n          4. Patient lacking capacity to consent to study participation\n\n          5. Unstable medical condition;\n\n          6. Use of benzodiazepines or barbiturates during the study and preceding two weeks;\n\n          7. Pharmacological immunosuppression;\n\n          8. Participation in a clinical trial with any investigational agent within two weeks\n             prior to study enrollment;\n\n          9. History of Epileptic Seizures or Epilepsy;\n\n         10. Contraindication for performing MRI scanning;\n\n         11. Contraindication for receiving TMS treatment according to a TMS questionnaire;\n\n         12. Pregnant women, and women who have the ability to become pregnant unless they are on\n             an acceptable method of contraception during the study.\n\n         13. Patients with personal history of any clinically defined neurological disorder,\n             including organic brain disease, epilepsy, stroke, brain lesions, or multiple\n             sclerosis; or personal history of previous neurosurgery or head trauma that resulted\n             in loss of consciousness.\n\n         14. Patients with  depression, bipolar disorder or psychotic disorders or any other\n             neurological or psychiatric condition (whether now or in the past), which the\n             Investigator finds as interfering with the study\n\n         15. Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more\n             than one year and or in remission less than 3 years)  or severe sleep deprivation\n\n         16. Patients treated with cholinesterase inhibitors, or memantine or Ginko-biloba will be\n             allowed to participate, if the treatment has started at least 6 months previous to\n             recruitment. The patients should keep their dose of medication during the whole trial\n             as prior to study begin.\n\n         17. Patients with metal in the head, except the mouth (i.e. cochlear implants, implanted\n             brain stimulators, aneurysm clips)\n\n         18. Patients with increased intracranial pressure\n\n         19. Cardiac pacemakers\n\n         20. Implanted neurostimulators\n\n         21. Implanted medication pumps\n\n         22. Intracardiac lines\n\n         23. Significant heart disease\n\n         24. Currently taking medication that lower the seizure threshold\n\n         25. Significant sleep deprivation and alcoholism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825317", 
            "org_study_id": "NRX-KOR1"
        }, 
        "intervention": [
            {
                "arm_group_label": "NeuroAD", 
                "description": "synchronized TMS+COGNITIVE TRAINING", 
                "intervention_name": "NeuroAD", 
                "intervention_type": "Device", 
                "other_name": "NICE"
            }, 
            {
                "arm_group_label": "Sham NeuroAD", 
                "description": "Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.", 
                "intervention_name": "Sham device", 
                "intervention_type": "Device", 
                "other_name": "Control device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alzheimer's disease", 
            "TMS", 
            "NeuroAd", 
            "cognitive training", 
            "ADAS-Cog"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daejeon", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Chungnam national university hospital, Daejeon Geriatric Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Alzheimer's disease assessment scale - cognitive test", 
            "measure": "ADAS-Cog", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825317"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Neuronix Ltd", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "company: K The Power", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chungnam national University Hospital, Daejeon Korea", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Neuronix Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}